WO2005013666A3 - Nouvel essai de translocation - Google Patents

Nouvel essai de translocation Download PDF

Info

Publication number
WO2005013666A3
WO2005013666A3 PCT/AU2004/001057 AU2004001057W WO2005013666A3 WO 2005013666 A3 WO2005013666 A3 WO 2005013666A3 AU 2004001057 W AU2004001057 W AU 2004001057W WO 2005013666 A3 WO2005013666 A3 WO 2005013666A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
level
novel
translocation assay
membrane
Prior art date
Application number
PCT/AU2004/001057
Other languages
English (en)
Other versions
WO2005013666A2 (fr
Inventor
David James
Roland Govers
Original Assignee
Garvan Inst Med Res
David James
Roland Govers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garvan Inst Med Res, David James, Roland Govers filed Critical Garvan Inst Med Res
Priority to AU2004262445A priority Critical patent/AU2004262445A1/en
Priority to US10/567,894 priority patent/US20070141635A1/en
Publication of WO2005013666A2 publication Critical patent/WO2005013666A2/fr
Publication of WO2005013666A3 publication Critical patent/WO2005013666A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un nouvel essai in vitro permettant de déterminer le niveau d'une protéine, en particulier d'une protéine de transport de la membrane, qui est située sur la membrane plasmatique d'une cellule, par rapport au niveau de cette même protéine dans la cellule. Le procédé de l'invention convient également pour déterminer le niveau de recyclage d'une protéine de transport de la membrane. L'invention concerne en outre un procédé permettant d'identifier un agent modulant la translocation d'une protéine, en particulier d'une protéine de transport de la membrane, sur la membrane plasmatique, et par conséquent, l'activité de cette protéine.
PCT/AU2004/001057 2003-08-08 2004-08-09 Nouvel essai de translocation WO2005013666A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2004262445A AU2004262445A1 (en) 2003-08-08 2004-08-09 Novel translocation assay
US10/567,894 US20070141635A1 (en) 2003-08-08 2004-08-09 Novel translocation assay

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003904237 2003-08-08
AU2003904237A AU2003904237A0 (en) 2003-08-08 2003-08-08 Novel translocation assay

Publications (2)

Publication Number Publication Date
WO2005013666A2 WO2005013666A2 (fr) 2005-02-17
WO2005013666A3 true WO2005013666A3 (fr) 2005-04-28

Family

ID=32476526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2004/001057 WO2005013666A2 (fr) 2003-08-08 2004-08-09 Nouvel essai de translocation

Country Status (3)

Country Link
US (1) US20070141635A1 (fr)
AU (1) AU2003904237A0 (fr)
WO (1) WO2005013666A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858957B2 (en) 2007-09-12 2014-10-14 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2189473A3 (fr) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
US20070053924A1 (en) * 2002-08-26 2007-03-08 Herve Tettelin Conserved and specific streptococcal genomes
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
EP2612679A1 (fr) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Compositions immunogènes pour une bactérie à gram positif telle que streptococcus agalactiae
JP2008544949A (ja) * 2004-10-08 2008-12-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 化膿性レンサ球菌のための免疫激性組成物および治療用組成物
PT2054431E (pt) * 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
WO2008108830A2 (fr) * 2006-10-30 2008-09-12 Novartis Ag Compositions immunogènes et thérapeutiques pour streptococcus pyogenes
US8263353B2 (en) 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
JP5656642B2 (ja) 2007-12-21 2015-01-21 ノバルティス アーゲー ストレプトリシンｏの変異体形態
CN102203604B (zh) * 2008-10-21 2014-09-10 托马斯·M·东德林格 用于防止组织样品中伪像的方法和组合物
GB0905140D0 (en) * 2009-03-25 2009-05-06 Isis Innovation Method
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2013016418A2 (fr) * 2011-07-27 2013-01-31 The Regents Of The University Of Michigan Sondes pour canaux ioniques et leurs procédés d'utilisation
EP2836506B1 (fr) 2012-04-10 2017-04-19 Oxford Nanopore Technologies Limited Pores de mutants de lysenin
WO2014018805A2 (fr) * 2012-07-25 2014-01-30 Theranos,Inc. Analyse d'image et mesure d'échantillons biologiques
WO2014108449A1 (fr) 2013-01-08 2014-07-17 Atrogi Ab Procédé de criblage, trousse, méthode de traitement et composé destinés à être utilisé dans une méthode de traitement
US9657348B2 (en) 2013-01-13 2017-05-23 Atrogi Ab Method of screening compounds for the treatment of diabetes
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
US9562860B1 (en) 2013-06-19 2017-02-07 Theranos, Inc. Methods and devices for sample analysis
US9891212B2 (en) 2013-12-16 2018-02-13 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
AU2015208919B9 (en) 2014-01-22 2021-04-01 Oxford Nanopore Technologies Limited Method for attaching one or more polynucleotide binding proteins to a target polynucleotide
EP3137490B1 (fr) 2014-05-02 2021-01-27 Oxford Nanopore Technologies Limited Pores mutants
WO2016004995A1 (fr) * 2014-07-09 2016-01-14 Atrogi Ab Procédé de criblage pour un composé apte à stimuler le transport de glucose dans des adipocytes bruns et/ou beige d'un mammifère, et ensemble pour l'utilisation dans un tel procédé
KR102222188B1 (ko) 2016-03-02 2021-03-02 옥스포드 나노포어 테크놀로지즈 리미티드 돌연변이체 기공
EP4122949B1 (fr) 2016-04-06 2024-06-05 Oxford Nanopore Technologies plc Pore mutant
GB201707122D0 (en) 2017-05-04 2017-06-21 Oxford Nanopore Tech Ltd Pore
EP3645552B1 (fr) 2017-06-30 2023-06-28 Vib Vzw Nouveaux pores protéiques
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
JP2020068696A (ja) * 2018-10-30 2020-05-07 国立研究開発法人産業技術総合研究所 細胞の糖取り込みを可視化するためのキメラタンパク質
WO2023081455A2 (fr) * 2021-11-08 2023-05-11 Memorial Sloan-Kettering Cancer Center Cellules immunitaires exprimant le transporteur de glucose 5 (glut5) et compositions et procédés les comprenant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989893A (en) * 1993-09-27 1999-11-23 University Of Massachusetts Medical Center Receptor-activated reporter systems
US6303373B1 (en) * 1999-06-09 2001-10-16 Whitehead Institute For Biomedical Research Method of measuring plasma membrane targeting of GLUT4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989893A (en) * 1993-09-27 1999-11-23 University Of Massachusetts Medical Center Receptor-activated reporter systems
US6632924B2 (en) * 1997-05-22 2003-10-14 Whitehead Institute For Biomedical Research Method of measuring plasma membrane targeting of GLUT4
US6303373B1 (en) * 1999-06-09 2001-10-16 Whitehead Institute For Biomedical Research Method of measuring plasma membrane targeting of GLUT4

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HANEY P.M.: "Intracellular targetting of the insulin-regulatable glucose transporter (GLUT4) is isoform specific and independent of cell type", THE JOURNAL OF CELL BIOLOGY, vol. 114, no. 4, August 1991 (1991-08-01), pages 689 - 699 *
SLOT J.W. ET AL.: "Translocation of the glucose transporter GLUT4 in cardiac myocytes of the rate", PROC. NATL. ACAD. SCI. USA, vol. 88, September 1991 (1991-09-01), pages 7815 - 7819 *
WANG ET AL.: "GLUT4 translocation by insulin in intact muscle cells: detection by a fast and quantitative assay", FEBS LETTERS, vol. 427, 1998, pages 193 - 197 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US8858957B2 (en) 2007-09-12 2014-10-14 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
US9102741B2 (en) 2007-09-12 2015-08-11 Novartis Ag GAS57 mutant antigens and GAS57 antibodies

Also Published As

Publication number Publication date
AU2003904237A0 (en) 2003-08-21
WO2005013666A2 (fr) 2005-02-17
US20070141635A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
WO2005013666A3 (fr) Nouvel essai de translocation
AU2002311773A1 (en) Labeled cells for use as an internal functional control in rare cell detection assays
AU2001251291A1 (en) Ubiquitin ligase assay
AU2002251574A1 (en) Electrochemical biosensors
WO2006124641A3 (fr) Anticorps diriges contre la mesotheline utiles pour des dosages immunologiques
AU9648301A (en) Assay for rapid detection of human activated protein c and highly specific monoclonal antibody therefor
WO2005118836A3 (fr) Essai d'activite de prolyl hydroxylase de hif
WO2003048300A3 (fr) Procedes d'identification de molecules cibles cellulaires
TW200641137A (en) A method for quantifying cholesterol of remnant-like particles lipoprotein, reagent and kit
MXPA02001307A (es) Deteccion de micro-organismos.
WO2005089505A3 (fr) Detection, isolement et utilisations de la renalase (monoamine oxydase de type c)
GB0208041D0 (en) Method of culturing animal cells
AU2002246792A1 (en) Identification of individual cells during kinetic assays
AU4985201A (en) Human gene critical to fertility
AU6043900A (en) Biosensor
WO2005089509A3 (fr) Systemes d'essai a haut debit et procedes pour identifier des agents qui modifient l'expression de proteines cellulaires
WO2007039699A3 (fr) Substrat proteique pour la detection de l'activite calpaine 3
WO2004005926A3 (fr) Expression d'antigene 5t4
WO2005014847A3 (fr) Reactifs, methodes et necessaires de detection d'enzymes pour l'alimentation des animaux
EP1356076A4 (fr) Procedes et compositions permettant l'extraction de proteines a partir de cellules
AU2003288621A1 (en) Rna bioassay
WO2004084708A3 (fr) Decouverte de la partie utilisable d'une courbe sigmoide
WO2004096833A3 (fr) Inducteurs d'expression de proteine de recombinaison
WO2004016743A3 (fr) Mise en culture de l'anaplasma
WO2004078783A3 (fr) Enzymes impliquees dans l'apoptose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004262445

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004262445

Country of ref document: AU

Date of ref document: 20040809

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004262445

Country of ref document: AU

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 2007141635

Country of ref document: US

Ref document number: 10567894

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10567894

Country of ref document: US